½ÃÀ庸°í¼­
»óǰÄÚµå
1561575

ºÎºñµ¿ È®Àå ±â±â ½ÃÀå º¸°í¼­ : Á¦Ç° À¯Çüº°, ÀýÂ÷º°, ȯÀÚ À¯Çüº°, ÃÖÁ¾ »ç¿ëÀÚº°, Áö¿ªº°(2024-2032³â)

Sinus Dilation Devices Market Report by Product, Procedure, Patient Type, End User, and Region 2024-2032

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: IMARC | ÆäÀÌÁö Á¤º¸: ¿µ¹® 136 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°èÀÇ ºÎºñµ¿ È®Àå ±â±â ½ÃÀå ±Ô¸ð´Â 2023³â 35¾ï ´Þ·¯¿¡ ´ÞÇß½À´Ï´Ù. IMARC GroupÀº ÇâÈÄ ½ÃÀåÀÌ 2032³â±îÁö 68¾ï ´Þ·¯¿¡ À̸¦ Àü¸ÁÀ̸ç, 2024³âºÎÅÍ 2032³â±îÁö 7.4%ÀÇ ¼ºÀå·ü(CAGR)À» ³ªÅ¸³¾ °ÍÀ¸·Î Àü¸ÁÇϰí ÀÖ½À´Ï´Ù.

dz¼± ºÎºñµ¿ ¼ºÇü¼ú·Îµµ ¾Ë·ÁÁø ºÎºñµ¿ È®Àå¼úÀº Æó¼âµÈ ºÎºñµ¿ Åë·Î¸¦ ¿­°í ÀûÀýÇÑ °ø±â È帧À» °¡´ÉÇÏ°Ô Çϰí ÀÚ¿¬ÀûÀÎ ¹è¼ö¸¦ ȸº¹½ÃŰ´Â Àúħ½À Ä¡·áÀÔ´Ï´Ù. ºÎºñµ¿ È®Àå¼úÀº ºÎºñµ¿ °³±¸ºÎÀÇ °³Å뼺À» °³¼±Çϰí, ±¹¼Ò ¾à¹°À» Åõ¿©Çϰí, ¼ö¼ú ÈÄ ¿°ÁõÀ» ¿ÏÈ­Çϱâ À§ÇØ ´Ù¾çÇÑ ÀÌ½Ä °¡´ÉÇÑ µµ±¸¸¦ »ç¿ëÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ÀåÄ¡´Â Á¶±â ȸº¹¿¡ µµ¿òÀÌ µÇ±â ¶§¹®¿¡ Àü ¼¼°èÀûÀ¸·Î ³­Ä¡¼º ¸¸¼º ºñ°­ ºÎºñµ¿¿°(CRS)À» Ä¡·áÇÒ ¶§ ±âÁ¸ ºÎºñµ¿ ±â±â¿¡ ºñÇØ ÁöÁö¸¦ ¹Þ°í ÀÖ½À´Ï´Ù. ÀÌ ¹Û¿¡, ü°ñµ¿À̳ª ´Ù¸¥ ºÎºñµ¿¿¡ °­ÇÑ ¿°ÁõÀÌ Àִ ȯÀÚ¿¡ ´ëÇØ¼­´Â ´Ù¸¥ ¼ö¼ú°ú Á¶ÇÕÇÒ ¼öµµ ÀÖ½À´Ï´Ù. ÇöÀç ¿©·¯ Á¦Á¶¾÷ü°¡ ¼ö¼ú Áß ÀåÄ¡ÀÇ À§Ä¡¸¦ °áÁ¤Çϱâ À§ÇÑ ¸¶ÀÌÅ©·Î ¼¾¼­¸¦ ÅëÇÕÇÑ ÀåÄ¡¸¦ ¹ßÇ¥Çϰí ÀÖ½À´Ï´Ù.

ºÎºñµ¿ È®Àå ±â±â ½ÃÀå µ¿Çâ :

ÄÚ Æú¸³, ÄÚ ±â°ü Æ©ºê, ¾Ë·¹¸£±â¼º ºñ¿°, ºñ°­ Áß°Ý ÆíÀ§, ¾È¸é°ñ ÀÌ»ó, ¾Æµ¥³ëÀÌµå ºÎÁ¾, ±¸°³¿­ µîÀÇ ¿äÀÎÀ¸·Î ÀÎÇØ ¸¸¼º ºÎºñµ¿¿°ÀÌ ¹ß»ýÇÒ °¡´É¼ºÀÌ ³ô½À´Ï´Ù. ÀÌ´Â ³ëÀÎ Àα¸¿¡¼­ ÀÌ·¯ÇÑ ¿äÀÎÀÇ À¯º´·üÀÌ Å©°Ô Áõ°¡ÇÔ¿¡ µû¶ó ½ÃÀå ¼ºÀåÀ» µÞ¹ÞħÇÏ´Â Áß¿äÇÑ ¿äÀÎ Áß ÇϳªÀÔ´Ï´Ù. ÀÌ ¿Ü¿¡µµ Á¾¾ç, ´ç´¢º´, ³¶Æ÷¼º ¼¶À¯Áõ, ¼¶¸ð ¿îµ¿ ÀÌ»óÁõ, Ä«¸£Å¸°Ô³Ê ÁõÈıº, Àΰ£ ¸é¿ª°áÇÌ ¹ÙÀÌ·¯½º(HIV) °¨¿°Áõ ȯÀÚ ¼ö°¡ Áõ°¡ÇÔ¿¡ µû¶ó ½ÃÀå ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀϹÝÀûÀ¸·Î ¼Ò¾Æ´Â ºÎºñµ¿¿°À» Æ÷ÇÔÇÑ ±Þ¼º ±â°üÁö¿°À» ÀÏÀ¸Å³ À§ÇèÀÌ ³ô½À´Ï´Ù. À̰ÍÀº ¾Æµ¿ÀÇ °Ç°­¿¡ ´ëÇÑ ºÎ¸ðÀÇ °ü½ÉÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ¼¼°è ºÎºñµ¿ È®Àå ¼ö¼ú°ú ºÎºñµ¿ È®Àå ±â±â¿¡ ´ëÇÑ ¼ö¿ä¸¦ À¯¹ßÇÕ´Ï´Ù. À̿ʹ º°µµ·Î ±âÁ¸ÀÇ °³º¹ ¼ö¼úº¸´Ù Àúħ½À ¼ö¼ú(MIS)ÀÇ »õ·Î¿î µ¿ÇâÀÌ ½ÃÀå¿¡ ±àÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀÇ·á ÀÎÇÁ¶ó °³¼± ¹× »õ·Î¿î ºÎºñµ¿ È®Àå ±â±â µµÀÔÀ» À§ÇÑ ÀÚ±Ý Á¶´Þ Áõ°¡´Â ½ÃÀå ±â¾÷¿¡°Ô À¯¸®ÇÑ ¼ºÀå ±âȸ¸¦ Á¦°øÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÀÌ º¸°í¼­¿¡¼­ ´Ù·ç´Â ÁÖ¿ä Áú¹®

  • 2023³â ¼¼°èÀÇ ºÎºñµ¿ È®Àå ±â±â ½ÃÀå ±Ô¸ð´Â?
  • 2024³âºÎÅÍ 2032³â±îÁö ¼¼°è ºÎºñµ¿ È®Àå ±â±â ½ÃÀåÀÇ ¿¹»ó ¼ºÀå·üÀº?
  • ¼¼°èÀÇ ºÎºñµ¿ È®Àå ±â±â ½ÃÀåÀ» °ßÀÎÇÏ´Â ÁÖ¿ä ¿äÀÎÀº ¹«¾ùÀΰ¡?
  • ¼¼°èÀÇ ºÎºñµ¿ È®Àå ±â±â ½ÃÀå¿¡ ´ëÇÑ COVID-19ÀÇ ¿µÇâÀº?
  • ¼¼°è ºÎºñµ¿ È®Àå ±â±â ½ÃÀåÀÇ Á¦Ç°º° ³»¿ªÀº?
  • ¼¼°è ºÎºñµ¿ È®Àå ±â±â ½ÃÀåÀÇ ´Ü°èº° ³»¿ªÀº?
  • ¼¼°è ºÎºñµ¿ È®Àå ±â±â ½ÃÀåÀÇ È¯ÀÚ À¯Çüº° ³»¿ªÀº?
  • ¼¼°è ºÎºñµ¿ È®Àå ±â±â ½ÃÀåÀÇ ÃÖÁ¾ »ç¿ëÀÚº° ³»¿ªÀº?
  • ¼¼°è ºÎºñµ¿ È®Àå ±â±â ½ÃÀåÀÇ ÁÖ¿ä Áö¿ªÀº?
  • ¼¼°è ºÎºñµ¿ È®Àå ±â±â ½ÃÀåÀÇ ÁÖ¿ä ¾÷ü ¹× ±â¾÷Àº?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹üÀ§ ¹× Á¶»ç ¹æ¹ý

  • Á¶»çÀÇ ¸ñÀû
  • ÀÌÇØ°ü°èÀÚ
  • µ¥ÀÌÅÍ ¼Ò½º
    • 1Â÷ Á¤º¸
    • 2Â÷ Á¤º¸
  • ½ÃÀå ÃßÁ¤
    • »óÇâ½Ä Á¢±Ù
    • ÇÏÇâ½Ä Á¢±Ù
  • Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ¼­¹®

  • °³¿ä
  • ÁÖ¿ä ¾÷°è µ¿Çâ

Á¦5Àå ¼¼°èÀÇ ºÎºñµ¿ È®Àå ±â±â ½ÃÀå

  • ½ÃÀå °³¿ä
  • ½ÃÀå ½ÇÀû
  • COVID-19ÀÇ ¿µÇâ
  • ½ÃÀå ¿¹Ãø

Á¦6Àå ½ÃÀå ³»¿ª : Á¦Ç°º°

  • dz¼± ºÎºñµ¿ È®Àå ±â±â
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • »ó¾Çµ¿ ÀÓÇöõÆ®
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • ÇÚµåÇïµå ±â±â
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • ³»½Ã°æ
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • ±âŸ
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø

Á¦7Àå ½ÃÀå ³»¿ª : ¼ö±âº°

  • µ¶¸³Çü
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • ÇÏÀ̺긮µå
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø

Á¦8Àå ½ÃÀå ³»¿ª : ȯÀÚ À¯Çüº°

  • ¼ºÀÎ
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • ¼Ò¾Æ
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø

Á¦9Àå ½ÃÀå ³»¿ª : ÃÖÁ¾ »ç¿ëÀÚº°

  • º´¿ø
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC)
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • ±âŸ
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø

Á¦10Àå ½ÃÀå ³»¿ª : Áö¿ªº°

  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • ÀϺ»
    • Àεµ
    • Çѱ¹
    • È£ÁÖ
    • Àεµ³×½Ã¾Æ
    • ±âŸ
  • À¯·´
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ¿µ±¹
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • ·¯½Ã¾Æ
    • ±âŸ
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ±âŸ
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ³»¿ª : ±¹°¡º°
    • ½ÃÀå ¿¹Ãø

Á¦11Àå SWOT ºÐ¼®

  • °³¿ä
  • °­Á¡
  • ¾àÁ¡
  • ±âȸ
  • À§Çù

Á¦12Àå ¹ë·ùüÀÎ ºÐ¼®

Á¦13Àå Porter's Five Forces ºÐ¼®

  • °³¿ä
  • ±¸¸ÅÀÚÀÇ Çù»ó·Â
  • °ø±Þ±â¾÷ÀÇ Çù»ó·Â
  • °æÀïµµ
  • ½Å±Ô ÁøÀÔ¾÷ÀÚÀÇ À§Çù
  • ´ëüǰÀÇ À§Çù

Á¦14Àå °¡°Ý ºÐ¼®

Á¦15Àå °æÀï ±¸µµ

  • ½ÃÀå ±¸Á¶
  • ÁÖ¿ä ±â¾÷
  • ÁÖ¿ä ±â¾÷ ÇÁ·ÎÆÄÀÏ
    • Aetna Inc.(CVS Health Corporation)
    • Dalent Medical
    • Innaccel Technologies Pvt. Ltd
    • Intersect ENT Inc.
    • Johnson & Johnson
    • Karl Storz SE & Co. KG
    • Medtronic plc
    • Meril Life Sciences Pvt. Ltd
    • Olympus Corporation
    • Sinusys Corporation
    • Smith & Nephew plc
    • Stryker Corporation
AJY 24.10.08

The global sinus dilation devices market size reached US$ 3.5 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 6.8 Billion by 2032, exhibiting a growth rate (CAGR) of 7.4% during 2024-2032.

Sinus dilation, also known as balloon sinuplasty, is a minimally invasive procedure that opens blocked sinus passages, allow adequate airflow, and restore natural drainage. It relies on various implantable devices to improve the patency of sinus openings, deliver local medication, and reduce postoperative inflammation. As these devices help in quick recovery, they are gaining traction over conventional sinus devices to treat chronic rhinosinusitis (CRS) refractory worldwide. Besides this, they can be combined with other techniques for patients with significant inflammation in the ethmoid or other sinuses. Nowadays, several manufacturers are introducing devices integrated with microsensors to determine device position during surgeries.

Sinus Dilation Devices Market Trends:

Factors like nasal polyps, nasotracheal tubes, allergic rhinitis, deviated septum, facial bone abnormalities, swollen adenoids, and cleft palate increase the likelihood of developing chronic sinusitis. This, coupled with a significant rise in the prevalence of these factors among the geriatric population, represents one of the key factors bolstering the market growth. In addition to this, the growing number of patients with tumors, diabetes, cystic fibrosis, ciliary dyskinesia, Kartagener syndrome, and human immunodeficiency virus (HIV) infection is contributing to market growth. Moreover, children generally have a higher risk of developing acute bronchitis, including sinusitis. This, in confluence with the increasing concerns among parents about the health of their children, is catalyzing the demand for sinus dilation surgeries and devices around the world. Apart from this, the emerging trend of minimally invasive surgeries (MIS) over conventional open surgeries is influencing the market positively. Furthermore, the improving healthcare infrastructure and rising funding to introduce novel sinus dilation devices are projected to offering lucrative growth opportunities to market players.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global sinus dilation devices market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on product, procedure, patient type and end user.

Breakup by Product:

  • Balloon Sinus Dilation Devices
  • Sinus Implants
  • Handheld Instruments
  • Endoscopes
  • Others

Breakup by Procedure:

  • Standalone
  • Hybrid

Breakup by Patient Type:

  • Adult
  • Pediatric

Breakup by End User:

  • Hospitals
  • Ambulatory Surgical Centers
  • Others

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Aetna Inc. (CVS Health Corporation), Dalent Medical, Innaccel Technologies Pvt. Ltd, Intersect ENT Inc., Johnson & Johnson, Karl Storz SE & Co. KG, Medtronic plc, Meril Life Sciences Pvt. Ltd, Olympus Corporation, Sinusys Corporation, Smith & Nephew plc and Stryker Corporation.

Key Questions Answered in This Report

  • 1. What was the size of the global sinus dilation devices market in 2023?
  • 2. What is the expected growth rate of the global sinus dilation devices market during 2024-2032?
  • 3. What are the key factors driving the global sinus dilation devices market?
  • 4. What has been the impact of COVID-19 on the global sinus dilation devices market?
  • 5. What is the breakup of the global sinus dilation devices market based on the product?
  • 6. What is the breakup of the global sinus dilation devices market based on the procedure?
  • 7. What is the breakup of the global sinus dilation devices market based on the patient type?
  • 8. What is the breakup of the global sinus dilation devices market based on the end user?
  • 9. What are the key regions in the global sinus dilation devices market?
  • 10. Who are the key players/companies in the global sinus dilation devices market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Sinus Dilation Devices Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Product

  • 6.1 Balloon Sinus Dilation Devices
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Sinus Implants
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Handheld Instruments
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Endoscopes
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Others
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast

7 Market Breakup by Procedure

  • 7.1 Standalone
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Hybrid
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Patient Type

  • 8.1 Adult
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Pediatric
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast

9 Market Breakup by End User

  • 9.1 Hospitals
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Ambulatory Surgical Centers
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Others
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Aetna Inc. (CVS Health Corporation)
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 SWOT Analysis
    • 15.3.2 Dalent Medical
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
    • 15.3.3 Innaccel Technologies Pvt. Ltd
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
    • 15.3.4 Intersect ENT Inc.
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
    • 15.3.5 Johnson & Johnson
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 Financials
      • 15.3.5.4 SWOT Analysis
    • 15.3.6 Karl Storz SE & Co. KG
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 SWOT Analysis
    • 15.3.7 Medtronic plc
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
      • 15.3.7.4 SWOT Analysis
    • 15.3.8 Meril Life Sciences Pvt. Ltd
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
    • 15.3.9 Olympus Corporation
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis
    • 15.3.10 Sinusys Corporation
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
    • 15.3.11 Smith & Nephew plc
      • 15.3.11.1 Company Overview
      • 15.3.11.2 Product Portfolio
      • 15.3.11.3 Financials
      • 15.3.11.4 SWOT Analysis
    • 15.3.12 Stryker Corporation
      • 15.3.12.1 Company Overview
      • 15.3.12.2 Product Portfolio
      • 15.3.12.3 Financials
      • 15.3.12.4 SWOT Analysis
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦